Results 151 to 160 of about 186,128 (186)

Two-year results of a treat-and-extend regimen with aflibercept for polypoidal choroidal vasculopathy

Graefe's Archive for Clinical and Experimental Ophthalmology, 2017
To evaluate the effects of aflibercept therapy using a treat-and-extend regimen on treatment-naïve polypoidal choroidal vasculopathy (PCV).In a retrospective interventional case series of 58 eyes of 58 patients with PCV, we assessed best-corrected visual acuity (BCVA), central macular thickness (CMT), central choroidal thickness (CCT), and number of ...
Dan, Călugăru, Mihai, Călugăru
openaire   +4 more sources

Intravitreal ranibizumab versus aflibercept following treat and extend protocol for neovascular age-related macular degeneration

Graefe's Archive for Clinical and Experimental Ophthalmology, 2019
To assess the morphological and functional outcome and stability of the "treat and extend" protocol using aflibercept compared to ranibizumab for the treatment of eyes with neovascular age-related macular degeneration.This retrospective study included 100 eyes of 94 patients with primary onset neovascular age-related macular degeneration followed up ...
Alaa Din Abdin, Shady Suffo, Fatima Asi, Achim Langenbucher, Berthold Seitz   +4 more
openaire   +2 more sources

OUTCOMES OF TREAT-AND-EXTEND USING AFLIBERCEPT IN TYPE 3 MACULAR NEOVASCULARIZATION

Retina
Purpose: To evaluate the clinical outcomes of a treat-and-extend regimen using aflibercept for Type 3 macular neovascularization. Methods: In this prospective phase four clinical trial, 25 patients with Type 3 macular ...
Jae Hui Kim, Yeji Kim, Sang Min Park, Han Joo Cho   +3 more
openaire   +1 more source

Reactivation of stable neovascular age‐related macular degeneration following treat‐and‐extend regimen discontinuation

Clinical & Experimental Ophthalmology
AbstractBackgroundTo describe the incidence and pattern of reactivation of neovascular age‐related macular degeneration (nAMD) following successful treatment with treat‐and‐extend intravitreal anti‐vascular endothelial growth factor therapy.MethodsConsecutive patients with treated nAMD who did not require further treatment over a 6‐month period and who
Jose Carlo M. Artiaga, Shiao Wei Wong, Deepthy Menon, Swetha Kumar, Pankaja Dhoble, Sridevi Thottarath, Luke Nicholson   +6 more
openaire   +2 more sources

RETROSPECTIVE REVIEW OF LUCENTIS “TREAT AND EXTEND” PATTERNS AND OUTCOMES IN AGE-RELATED MACULAR DEGENERATION

Retina, 2016
To assess patterns and outcomes of a "Treat and Extend" dosing regimen of ranibizumab in patients with age-related macular degeneration.Three hundred and thirty two treatment-naive age-related macular degeneration patients starting therapy with ranibizumab between January 1, 2011, and June 30, 2012, at the Ivey Eye Institute were reviewed, and 79 met ...
Yufeng N, Chen, Anne-Marie, Powell, Alex, Mao, Tom G, Sheidow   +3 more
openaire   +2 more sources

Treat-and-extend approach with aflibercept: Effects on different subtypes of age-related choroidal neovascularisation

Archivos de la Sociedad Española de Oftalmología (English Edition), 2017
To describe functional/morphological outcomes of treat-and-extend (TAE) with aflibercept in different subtypes of neovascularizations (CNV) secondary to exudative age-related macular degeneration (AMD).Retrospective study was conducted on 30 eyes of 30 patients treated with 2 mg-aflibercept according to a TAE protocol.
V, Castro-Navarro, E, Cervera-Taulet, J, Montero-Hernández, C, Navarro-Palop   +3 more
openaire   +2 more sources

“TREAT AND EXTEND” AMPHOTERICIN B IN POSTOPERATIVE DESCEMET MEMBRANE ENDOTHELIAL KERATOPLASTY FUNGAL ENDOPHTHALMITIS

RETINAL Cases & Brief Reports
Background/Purpose: This is a case report on providing amphotericin B for postoperative fungal endophthalmitis with a treat-and-extend schedule. This study explores a deviation from the typical standard of care, given the circumstances encountered by this patient.
Sparsh Jain, Roxana Godiwalla, Hart Moss
openaire   +1 more source

Comparison of two different treat‐and‐extend protocols with aflibercept in wet age‐related macular degeneration

Acta Ophthalmologica, 2019
AbstractPurposeTo optimize the aflibercept treat‐and‐extend protocol in wet age‐related macular degeneration (wAMD).MethodsA prospective randomized clinical trial consisting of 52 eyes from 52 patients with treatment‐naïve wAMD. Patients received three monthly aflibercept injections and were then randomized 1:1 to two different dosing protocols.
Taipale Claudia, Laine Ilkka, Lindholm Juha-Matti, Tuuminen Raimo, Taipale Claudia, Laine Ilkka, Lindholm Juha-Matti, Tuuminen Raimo   +7 more
openaire   +2 more sources

The itinerant oscillator treated and extended in terms of a mori continued fraction

Chemical Physics Letters, 1977
Abstract The angular velocity and orientational autocorrelation function of a disk are evaluated using a four-variable Mori formalism. It is pointed out that the equivalent three-variable formalism is formally identical to the inertia-corrected itinerant oscillator model developed recently by Coffey et al.
openaire   +1 more source

Retinopathy Regression with Treat and Extend Ranibizumab for Diabetic Macular Edema

Ophthalmology, 2018
John F. Payne, W. Lloyd Clark, Beau B. Bruce, Charles C. Wykoff, David M. Brown, Brandon M. Menke, Shawn M. Iverson, Keri F. Allen, David S. Boyer, John F. Payne, W. Lloyd Clark, John A. Wells, David L. Johnson, Charles C. Wykoff, David M. Brown, Matthew Benz, Eric Chen, Richard H. Fish, Rosa Y. Kim, James C. Major, Ronan E. O’Malley, Amy C. Schefler, Ankoor R. Shah, Tien P. Wong, David S. Boyer, Roger L. Novack, Thomas G. Chu, Firas Rahhal, Homayoun Tabandeh, Richard H. Roe, Pouya N. Dayani, David Liao, Alexander Walsh, Daniel D. Esmaili   +33 more
openaire   +2 more sources